Heidi invests in Headline
Funding Provisional 86% confidence first seen
Heidi (Heidi Health / Heidi Health Trading), a Melbourne-based health AI startup, raised a combined $340 million in new funding, including a $100 million Series C led by Blackbird with participation from existing backers Phoenix Court, Point72 Private Investments, and Headline, and an additional $240 million in growth investment from General Catalyst’s Customer Value Fund (CVF). The round values the company at $900 million, and the CVF growth capital is described as revenue-based growth financing repaid from sales-related revenue to avoid diluting existing investors. The funding is intended to deepen global deployment of its “AI Care Partner” (e.g., Scribe and Evidence) and supports expansion efforts including regulatory work for advanced clinical features in Europe and the UK.
The deal
Heidi $340 million Series C · announced 22 Sep 2026
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Heidi, a Melbourne-based health AI startup, raised $340 million in combined financing at a reported $900 million valuation, including a $100 million Series C with participation from Headline and a $240 million growth investment. The company said the new capital will fund deeper deployment of its AI care products and expansion in Europe, including DACH hiring and regulatory work in Europe and the UK.
- Why it matters
- For leadership teams evaluating health AI vendors or competitive moves, this financing gives Heidi more capacity to scale sales, hiring, and product rollout in key European markets. The reported use of growth financing alongside equity suggests Heidi is trying to accelerate expansion while limiting dilution, which can support longer-term execution if revenue growth holds; this matters for counterparties assessing Heidi’s staying power and pace of market entry.
- Evidence
- The provided coverage comes from a single article by Trending Topics EU, which reports the $340 million total, $900 million valuation, investor participation including Headline, and expansion plans in DACH and for European and UK regulatory work. Because only one outlet is provided here, the facts are not independently corroborated within this record.
- What remains uncertain
- The coverage does not detail the terms, repayment mechanics, or operating covenants of the growth financing, so any conclusions about financial flexibility depend on the assumption that the structure works as described. It also does not verify current revenue scale, customer adoption, or regulatory timelines, leaving open how quickly Heidi can convert funding into durable European deployment.
- Monitor next
- Watch for concrete signals of European execution: announced DACH leadership hires, regulatory approvals or filings for advanced clinical features, and disclosed customer deployments in Europe or the UK.
Analytical support, not advice — assumptions and open questions stated above.